GH1
Overview
GH1 (Growth Hormone 1) encodes the canonical pituitary growth hormone, a cytokine that signals through GHR to activate JAK2/STAT5, PI3K/AKT, and MAPK pathways. In breast cancer, autocrine/paracrine GH1 signaling has been implicated in cell survival and proliferation. GH1 appeared with evidence of positive selection in a WGS study of triple-negative breast cancer, suggesting a potential somatic driver role in a subset of tumors.
Alterations observed in the corpus
- Evidence of positive selection (q < 0.1) in TNBC WGS cohort (BCCRC, 65 tumors); identified by driverNet analysis as enriched for somatic mutations beyond background mutation rate PMID:22495314
Cancer types (linked)
- TNBC (triple-negative breast cancer): GH1 showed positive selection signal in a 65-tumor WGS cohort; functional driver status not directly validated PMID:22495314
Co-occurrence and mutual exclusivity
- No co-mutation patterns reported in this corpus.
Therapeutic relevance
- GH signaling pathway represents a potential therapeutic target; no direct drug evidence in this corpus.
Open questions
- Whether GH1 mutations confer driver function in TNBC or represent false-positive selection signals in small cohorts requires functional validation PMID:22495314
Sources
This page was processed by entity-page-writer on 2026-05-06.